ఇంటర్నేషనల్ జర్నల్ ఆఫ్ ఫిజికల్ మెడిసిన్ & రిహాబిలిటేషన్
అందరికి ప్రవేశం

నైరూప్య

Prognosis of Heart Failure and Sympathetic Nerve Activity

Shinya Minatoguchi

The prognosis of heart failure is poor and plasma noradrenaline level is a good predictor of the survival rate of heart failure patients. Sympathetic nerve activity is augmented in patients with heart failure as evidenced by a higher noradrenaline release rate from the sympathetic nerve endings. Drugs for heart failure such as β-blockers, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, mineralocorticoid antagonists, ivabradine, Angiotensin Receptor-Neprilysin Inhibitor (ARNI), and Sodium-Glucose Transport Protein 2 (SGLT2) inhibitors have clinical evidences for improving prognosis of heart failure in large randomized-controlled clinical trials. Interestingly, the same characteristics in common of these drugs is to reduce sympathetic nerve activity. In addition, cardiac rehabilitation which causes a better prognosis of heart failure reduces the sympathetic nerve activity. In conclusion, to optimize excessively augmented sympathetic nerve activity may be related to an improvement of prognosis of heart failure.